Truvian Sciences Raises $105M Series C To Fund Development Of Point-Of-Care Testing Platform
Executive Summary
Truvian Sciences will use the proceeds to fund regulatory submission for its POC testing system in Europe and the US with hopes to bring to retailers, pharmacies, health systems in 2022.
You may also be interested in...
Exec Chat: Dexcom’s CEO Bullish On Year Ahead With G7 CGM Launch, Dexcom One CGM Expansion
In an interview with Medtech Insight following the J.P. Morgan Health Care Conference, Dexcom CEO Kevin Sayer discussed marketing plans for the next-generation G7 continuous glucose monitoring system and for the simpler CGM, Dexcom One, and outlined plans ahead.
CES 2022: The Intersection Of Digital Health And Consumer Tech
CES 2022 was missing some marquee names due to the latest coronavirus surge, but there was still plenty to take in at the intersection of digital health and consumer tech. In this roundup, In Vivo highlights some standouts, with commentary from company leaders.
Minute Insight: Sema4 To Acquire Genomics Company GeneDx For $623M To Strengthen Clinical Data Platform
Genetic testing company Sema4 announced plans to buy GeneDx to strengthen Sema4’s health intelligence and genomic screening offers. The combined company is expected to generate $350m in pro forma 2022 revenue.